Persistence of Immune Response After Vaccination With MCC

Phase 4CompletedNCT00310687

Novartis1,244 enrolled

Overview

Persistence of Immune response after vaccination with MCC

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

1,244

Conditions

Prevention of Meningococcal Infection

Interventions

BLOOD DRAWPROCEDURE

Eligibility

Sex: ALLMin age: 11 YearsMax age: 20 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * healthy adolescents vaccinated with Meningococcal C Conjugate vaccine Exclusion Criteria: * ascertained or suspected disease caused by N. meningitidis * household contact with individuals with proven N. meningitidis serogroup C infection * significant acute or chronic infections * any other serious disease

Locations (1)

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital

Headington, Oxfordshire, United Kingdom

Outcomes

Primary Outcomes

persistence of memory response to N. meningitidis serogroup C as measured by serum bactericidal activity at one year after either a challenge with 1/5 of a dose of Meningococcal A/C Polysaccharide vaccine or a booster dose of MenC Vaccine.

Secondary Outcomes

Evaluation and comparison of the persistence of antibodies against N. meningitidis serogroup C as measured by hBCA

Evaluation of the immunological response (ELISA) to N. meningitidis serogroup C

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.